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Despite its increasing clinical use, almost no data are currently available about paclitaxel effects on non-cancerous mammary epithelial
cells. We have previously established paclitaxel-resistant sub-cell lines (paclitaxel-surviving populations, PSPs; n¼20), and sensitive
controls (control clones, CCs; n¼10), from the untransformed human mammary epithelial cell line HME1. In this study, we aimed to
establish whether paclitaxel resistance was associated with a modified sensitivity to paclitaxel-induced aneuploidy. For this purpose,
we analysed basal and paclitaxel-induced chromosome missegregation, apoptosis and aberrant spindle multipolarisation as well as
microtubular network composition for each subline. PSP sublines showed higher basal and paclitaxel-induced chromosome
missegregation than the CC sublines. This phenomenon was associated with resistance to paclitaxel-induced apoptosis. No significant
difference in paclitaxel-induced spindle pole abnormalities between CC and PSP sublines was found. Besides, we showed that a
majority of PSPs display a constitutively disrupted microtubular network composition due to aberrant tubulin expression and post-
translational modifications. These results clearly indicate that paclitaxel resistance in untransformed human mammary epithelial cells is
related to an increased susceptibility to acquire aneuploidy in response to this agent. The consequences of these paclitaxel-associated
alterations could be deleterious as they can potentially trigger tumorigenesis.
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Cytotoxicity is a desirable consequence of cancer chemotherapy. In
most tumour cells, induction of genotoxic damage by anticancer
agents favours cell death (Colella et al, 1999; Branch et al, 2000).
However, increased genetic damages could also have adverse
consequences if the affected cells are not malignant. In fact, it has
been previously shown that genetic instability, characterised by an
abnormal number of chromosomes, is associated with secondary
malignancies. Thus, consideration of the potential aneugenicity of
chemotherapy to humans is a necessary adjunct to its clinical use.
Paclitaxel is a chemotherapeutic agent that is frequently used in
several human cancers, including lung, ovarian and breast cancer.
Several previous works have addressed the aneugenic potential of
this agent in various in vitro and in vivo models (Tinwell and
Ashby, 1994; Jagetia and Adiga, 1995; Jagetia and Nayak, 1996;
Digue et al, 1999; Galmarini et al, 2007). However, despite its
increasing use, almost no data are currently available concerning
its effects in normal human mammary epithelial cells. In a
precedent work, we described that sub-cell lines of untransformed
human mammary epithelial cells (HME1) were able to survive to a
1-week paclitaxel treatment (paclitaxel-surviving populations,
PSPs) (Galmarini et al, 2006). In most of these sublines, the
emergence of a transitory or stable drug resistance phenotype was
related to the inactivation of p21/WAF1 protein.
In this study, we sought to determine whether paclitaxel
resistance could be related to a modified sensitivity to paclitaxel
aneugenicity. For this purpose, we firstly assayed whether
paclitaxel treatment of PSPs and control clones (CCs) sublines
induced alterations typically associated to aneuploidy appearance
(chromosome missegregation and apoptosis defect). We secondly
analysed the constitutive microtubular network composition and
the aberrant spindle multipolarisation process after paclitaxel
exposure in these sublines as potential causes for differential effect
of paclitaxel on chromosomal stability. Our results show that
paclitaxel resistance in untransformed mammary epithelial cells,
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s(St Quentin Fallavier, France). Mouse fluorescein isothiocyanate
(FITC)-conjugated anti-human a-tubulin, mouse anti-human
g-tubulin and rabbit tetramethylrhodamine isothiocyanate
(TRITC)-conjugated anti-mouse IgG antibodies were purchased
from DAKO (Glostrup, Denmark). Antibodies against a-tubulin
(B-5-1-2), acetylated tubulin (6-11B-1), tyrosinated tubulin (Tub-
1A2), b-tubulin (Tub 2.1) and b-actin (AC-15) were purchased
from Sigma (St Quentin Fallavier, France); antibodies against class
IV b-tubulin isotype were purchased from Biogenex (San Ramon,
CA, USA). Class III b-tubulin isotype (TUJ1 clone) was kindly
provided by Anthony Frankfurter (University of Virginia, Char-
lottesville, VA, USA).
Obtention of PSPs
HME1 cells were purchased from ATCC collection (hTERT-HME1,
telomerase-immortalised human mammary epithelial cells that
stably express the telomerase catalytic subunit, hTERT). Paclitaxel-
surviving populations were obtained from HME1 cells as reported
previously (Galmarini et al, 2006). Briefly, HME1 cells were seeded
onto 20 separate 96-well plates at a concentration of 100cells/well.
The following day, treatment with paclitaxel started at a dose of
10pM over a period of 7 days. Paclitaxel-surviving Populations
were allowed to grow for 2–3 weeks in paclitaxel-free culture
medium. Wells containing PSPs were harvested, frozen and
expanded in drug-free medium for experimental studies. As a
control, 10 clones of HME1 cells (CCs) were obtained by limiting
dilution (0.1cell/well) with no exposure to the drug.
Cytokinesis-block micronucleus assay
CC and PSP cells were seeded at a concentration of 10
6cellsml
 1.
Paclitaxel was added at two different concentrations (1 and 20nM).
After 6h of paclitaxel treatment, cytochalasin-B (5mgml
 1) was
added and cells were incubated at 371C for 24h and then fixed in
100% methanol. DNA was counterstained with Hoechst 33258
(5mgml
 1). Coverslips were examined with an Axioplan micro-
scope (Carl Zeiss, Sartrouville, France) using a Zeiss  100 1.3 oil-
immersion objective. Pictures were acquired by using a confocal
laser scanning TCS SP2 microscope (Leica, Le Pecq, France) and
a  63 oil-immersion objective. The main nucleus and micronuclei
showed bright blue fluorescence (Figure 1B). The micronucleation
index was determined for each subline by the use of two
independent cytokinesis-block micronucleus (CBMN) assays. Each
assay consisted in two micronuclei scoring in a minimum of 200
binucleated cells per experimental condition (total score on
400 cells). Criteria for scoring micronuclei in binucleated cells in
the CBMN assay were described in detail by Fenech (2000). After
24h of single cytochalasin-B treatment, the mean frequency of
binucleated cells in CC and PSP were 55.1 and 60.1%, respectively.
Western blots
Protein expression was determined by Western blot analysis in CC
and PSP cells at basal conditions as described previously
(Galmarini et al, 2001). Horizontal scanning was performed on
Western blots by acquisition into Adobe Photoshop software
(Apple, Cupertino, CA, USA).
Apoptosis detection
Apoptotic index was calculated as the percentage of cells showing
apoptotic morphology revealed by 5mgml
 1 Hoechst 33258
(Sigma, St Quentin Fallavier, France) staining of nuclei, after
72h paclitaxel treatment (1 or 20nM) or without treatment. For
each experimental condition, a minimum of 200 cells per subline
were analysed. Apoptosis was also evaluated in cytochalasin-B-
treated cells, with or without 30h paclitaxel treatment. For each
independent CBMN assay, a minimum of 300 cells were analysed.
Double-immunofluorescence staining
CC and PSP were grown on glass coverslips and treated for 24h
with paclitaxel at two different dose levels: 1 and 20nM. To assay
mitotic spindle pole impairments, cells were fixed with 4%
paraformaldehyde and then permeabilised with 1% Triton X-100
in phosphate-buffered saline (PBS). After incubation with a
blocking solution (5% bovine serum albumin (BSA) in PBS) for
30min, cells were incubated with primary mouse anti-human
g-tubulin antibody diluted 1/1000 for 1h at 371C in a humid
chamber. After three washes with a PBS/BSA1% solution,



















Figure 1 Effect of 1 and 20nM paclitaxel on microtubular network and chromosome segregation in untransformed human mammary epithelial cells. (A)
Immunostaining of a-tubulin (green) in untreated (CTRL), 1 and 20nM paclitaxel-treated (PTX 1 and 20nM) HME1 cells. White arrows indicate microtubule
bundles. Scale bar, 10mm. (B) Micronucleus detection in paclitaxel-treated PSP and CC cells by CBMN assay. Briefly, 10
6 cellsml
 1 were seeded 24h before
paclitaxel (PTX) treatment (24h). Cytochalasin-B (CytoB) at 5mgml
 1 was added in culture media 6h after the beginning of paclitaxel exposure (6h). After
30h of paclitaxel treatment, cells were fixed by methanol, DNA was stained with Hoechst 33258 and binucleated cells with micronuclei (MN) were scored.
White arrows indicate micronuclei in binucleated cytokinesis-blocked HME1 cells treated by 1nM paclitaxel. Scale bar, 10mm. CBMN, cytokinesis-block
micronucleus.
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santi-mouse IgG secondary antibody. Then cells were incubated
with a FITC-conjugated mouse anti-human-a-tubulin diluted
1/100. Finally, DNA was counterstained by the addition of Hoechst
33258 (1mgml
 1) for 5min. Cells were observed with a Zeiss
Axioplan microscope using a Zeiss  100 1.3 oil-immersion
objective. The spindle pole abnormalities were scored in a
minimum of 300 mitotic cells per subline and for each condition
(baseline, 1 and 20nM paclitaxel).
Time-lapse imaging
We established HME1 cell line expressing histone H2B-GFP (H2B-
GFP) by stably transfecting hTERT-HME1 cells with plasmid
pBOS-H2BGFP (BD Biosciences, Erembodegem, Belgium) under
blasticidin selection (5mgml
 1). Exponentially growing cells were
plated on six-well culture plate and incubated with paclitaxel (1nM
for 24h). Images were acquired on a Zeiss Axiovert photomicro-
scope with a PowerShot G5 Digital Camera (Canon, Courbevoie,
France) under 371C heated atmosphere. Together with the
fluorescent images, transmitted light (differential interference
contrast optics) images were acquired. Data were analysed using
the Image J software.
Statistical analysis
The differences between groups were tested by the Mann–Whitney
U non-parametric test using the statistical package SPSS V10t.
The level of significance used in all the analyses was Po0.05.
RESULTS
Paclitaxel induces persistent chromosome missegregation
in PSP but not in CC sublines
To evaluate the chromosome segregation process after paclitaxel
treatment in CC and PSP sublines, we performed CBMN assays.
These assays were carried out without the use of specific markers
of chromosomes, and thus estimated the global missegregation
process but did not specify associated chromosome aberrations
(for example, nucleoplasmic bridges, chromosome non-disjunc-
tion and breakage). We decided to test effects of 1 and 20nM
paclitaxel on chromosome segregation, as these two doses were
previously found to be the paclitaxel IC20 and IC80 in HME1 cell
line (Galmarini et al, 2006). Moreover, these doses act differentially
to induce cell death in untransformed mammary cells. As shown in
Figure 1A, 1nM paclitaxel did not cause massive disorganisation of
microtubule network, whereas 20nM paclitaxel induced micro-
tubule bundles in HME1 cells.
At baseline conditions, none of the CCs presented binucleated
cells with micronuclei (Figure 1B; Table 1). In contrast, PSPs
showed basal micronucleation (mean frequency of binucleated
cells with micronuclei¼4.9%). This increased frequency was due
to four PSPs (PSP2, PSP4, PSP6 and PSP21; ranging from 16.7 to
40%) showing high basal micronucleation (Supplementary Table
1). Hence, some PSP sublines present constitutive chromosome
aberrations compared with the sensitive CC sublines.
At dose of paclitaxel 1nM, 60% (6/10) of CCs showed
micronucleation in binucleated cells (Supplementary Table 1)
with a mean frequency of 1.1% (ranging from 0 to 4.1%). Paclitaxel
at the same dose also increased the frequency of micronucleation
in PSPs. After this treatment, 80% of PSPs (16/20) showed
binucleated cells with micronuclei; the mean frequency of
micronucleation was 4.9% (range: 0–14.6%) (Table 1 and
Supplementary Table 1). Strikingly, the four PSPs that shared a
high basal micronucleation (PSP2, PSP4, PSP6 and PSP21) showed
a decreased micronucleation after 1nM paclitaxel exposure.
After 20nM paclitaxel exposure, massive cell death induced in
CC sublines during the CBMN assay did not permit to score
micronucleation in binucleated cells (Table 1, Supplementary
Table 1). In contrast, at the same time point, 80% of PSP (16/20)
sublines presented binucleated cells with micronuclei after drug
treatment (Supplementary Table 1). Besides, the mean frequency
of micronucleation in PSP binucleated cells was 42.5% (Table 1).
PSP sublines are resistant to paclitaxel-induced apoptosis
We sought to determine if the increased paclitaxel-induced
chromosome aberrations observed in PSPs was associated with a
defect of paclitaxel-induced cell death. For this purpose, we treated
all sublines with this agent at doses of 1 and 20nM, for 72h, and we
evaluated the apoptotic index (Table 1). In CC cells, paclitaxel
treatment induced apoptosis in a dose-dependent manner (1nM:
3.5%; 20nM: 62.6%). Similarly, PSPs showed a dose-dependent
paclitaxel-induced apoptosis; however, apoptotic index was
significantly lower in PSP than in CC sublines (1nM: 1.2%,
Po0.05; 20nM: 34.5%, Po0.001).
To establish a correlation between cell death and micronuclea-
tion in CCs and PSPs, we counted apoptosis in those slides used for
micronucleation counting by CBMN assay. Notably, a similar
significant apoptotic tendency than that observed after 72h was
already observed in PSP compared with CC sublines after 30h of
combined 20nM paclitaxel-cytochalasin-B treatment (CC: 45.1%,
PSP: 35.4%, Po0.05; Supplementary Figure 1). This result was
corroborated by the observation of a significantly lower binuclea-
tion in CC compared with PSP sublines, after 20nM paclitaxel
treatment, indicative of an increased cell death and/or cell-cycle
delay in these sublines (CC: 1.0%, PSP: 6.0%, Po0.01; Supple-
mentary Table 2). When performing a more detailed analysis, we
observed that ‘unstable’ PSP sublines (U-PSP), namely those that
showed constitutive chromosome segregation defect (PSP2, PSP4,
PSP6 and PSP21; Table 1), exhibited significantly more apoptosis
than stable PSP sublines (S-PSP) when analysed after combined
1n M paclitaxel-cytochalasin-B treatment (U-PSP: 13.2%, S-PSP:
4.1%, Po0.05; Supplementary Figure 1).
Table 1 Micronucleation, apoptosis and spindle pole status in CC and PSP sublines after paclitaxel treatment
MN-BN
a Apoptosis
b Spindle pole status
c









20nM SP¼2S P 42S P ¼2S P 42S P ¼2S P 42
CC 0.0 1.1 ND 0.2 3.5 62.6 95.5 4.5 86.0 13.9 26.8 73.2
PSP 4.9 4.9* 42.5 0.5 1.2* 34.5*** 95.1 4.9 92.7 7.3 14.8 85.2
PSP, paclitaxel-surviving population.
aPercentage of binucleated cells showing micronucleation; values represent mean percentage of micronucleated cells in CC (n¼10) and PSP
subline (n¼20) groups.
bPercentage of cells showing apoptotic morphology; values represent mean percentage of apoptotic cells in CC (n¼10) and PSP subline (n¼20)
groups.
cPercentage of mitotic cells with 2 (SP¼2) or more spindle poles (SP42); values represent mean percentage of each category in CC (n¼10) and PSP subline (n¼20)
groups. *Po0.05, ***Po0.001, comparison between CC and PSP values. ND, not determined.
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sPSP sublines display constitutive disruptions of the
microtubular network composition
Numerous authors suggested that alterations of microtubule
dynamics could lead to chromosome missegregation and aneu-
ploidy (ter Haar et al, 1996; Sorger et al, 1997; Rosa et al, 2006).
Moreover, it is well established that composition of microtubule
network – particularly tubulin isotype expression and tubulin
post-translational modifications – closely influences microtubule
dynamics and resistance to paclitaxel (Ohta et al, 1994; Kavallaris
et al, 1997; Ranganathan et al, 1998; Carles et al, 1999; Banerjee,
2002). For this reason, we decided to investigate the microtubular
network composition in PSP compared with CC sublines. We thus
analysed the expression of total a- and total b-tubulin, acetylated-
and tyrosinated-a-tubulin, and class III and class IV b-tubulin. In
the CC, total a- and total b-tubulin were uniformly expressed
(Figure 2). The levels of protein expression of acetylated a-tubulin
and tyrosinated a-tubulin were unchanged between the different
CCs; however, the levels of protein expression of acetylated
a-tubulin were low compared with those observed for tyrosinated
a-tubulin. Class III and class IV b-tubulins were similarly
expressed in the CCs.
In the PSPs, total a-tubulin expression was expressed in similar
levels in all the sublines. However, total b-tubulin protein content
was highly altered in several PSP sublines including PSP1, PSP7,
PSP16, PSP19, PSP43 and PSP45 (Figure 2). Indeed, these sublines
presented a decreased expression of total b-tubulin compared with
CCs and other PSPs. When analysing the expression of acetylated
a-tubulin, we observed that protein levels were different between
the different sublines, with higher contents of acetylated tubulin
protein in PSP1, PSP2, PSP3, PSP4, PSP19, PSP21, PSP32 and
PSP45. In these PSPs, compared with the CCs, the acetylated a-
tubulin was found to be overexpressed. These variations in protein
expression were not observed for tyrosinated a-tubulin. Compared
with CCs, the amounts of class III b-tubulin were greatly decreased
in PSP1, PSP16, PSP19, PSP20, PSP38 and PSP43. In contrast PSP2,
PSP4, PSP22, PSP25 and PSP32 presented higher levels of class III
b-tubulin than those observed in CC sublines. Finally, the amounts
of class IV b-tubulin showed to be highly decreased in PSP1, PSP2
and PSP4. These data indicate that the majority of PSP sublines
exhibit a disrupted microtubular network when compared with
sensitive sublines.
PSP and CC sublines undergo dose-dependent aberrant
spindle multipolarisation after paclitaxel treatment
We aimed to verify whether chromosome missegregation process
observed in PSPs could be associated to aberrant mitotic spindle
polarisation. For this purpose, we evaluated the spindle pole status
by double-immunofluorescence staining of a-tubulin and g-tubulin
in untreated and paclitaxel-treated (1 and 20nM) PSP sublines
compared with CC sublines (Figure 3A, Table 1). Percentage of
normal bipolar and multipolar mitoses was determined as
described in Material and Methods.
At baseline, the vast majority of mitoses in CC sublines were
normal, with almost all cells showing a bipolar spindle (Table 1).
When treated with paclitaxel, the CC cells revealed a dose-
dependent increase of mitotic multipolarisation (1nM: 13.9%;
20nM: 73.2%). Similarly, at baseline, most of PSPs had normal
mitoses with 95.1% of cells showing a bipolar spindle (Table 1).
When treated with paclitaxel, PSPs displayed a mean percentage of
multipolar mitoses of 7.3 and 85.2% after 1 and 20nM paclitaxel
exposure, respectively. In this sublines group, the percentage of
mitoses with more than two poles also increased in a dose-
dependent manner (Table 1). Notably, compared with CCs, PSPs
seemed to show less mitotic multipolarisation after 1nM paclitaxel
treatment; in contrast, PSP sublines seemed to show more mitotic
multipolarisation after 20nM; however, these differences were not
statistically significant (P40.05).
To confirm that the previously observed paclitaxel-associated
spindle multipolarisation in fixed samples were not due to
methodological artifacts, we evaluated the real-time effects of
paclitaxel in the HME1 cell line stably expressing a histone H2B-
green fluorescent protein (GFP). Expression of this fusion protein
allows sensitive analysis of chromosome dynamics as these
structures are fluorescently labelled in living cells (Kanda et al,
1998). The cell divisions observed in the control situation
(Figure 3B) were highly comparable with our observations in
fixed samples. This implies that the intensity of the lamp beam did
not cause significant cell-cycle arrest and predominantly allowed
mitoses to occur normally.
Mitotic progression was analysed on real time in 1nM paclitaxel-
treated cells (n¼10) compared with untreated cells (n¼10)
(Figure 3B–C). Untreated cells generally, completed metaphase–
telophase progression in approximately 25min (Figure 3B). In
contrast, most of the 1nM paclitaxel-treated cells showed delayed
mitosis and aborted telophase, especially in cells in which
appearance of multipolar spindle was observed (Figure 3C). After
paclitaxel exposure, most of the recorded multipolarised mitoses
led to initial metaphase arrest or aborted telophase followed by
irreversible metaphase-like arrest characterised by unaligned
chromosomes (Figure 3C and data not shown).
DISCUSSION
In a precedent work, we have shown that paclitaxel-resistant
sublines (PSPs) can be established from an untransformed human
mammary epithelial cell line (Galmarini et al, 2006). In this study,
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Figure 2 Microtubular network composition in CC and PSP sublines. Expression of total a-tubulin (Alpha), b-tubulin (Beta), acetylated a-tubulin (Ac),
tyrosinated a-tubulin (Tyr), class III b-tubulin (III), class IV b-tubulin (IV) and b-actin (Actin) were analysed by Western blot in whole-cell lysates of
exponentially growing cells from CC (1–10) and PSP (1–46) sublines. CC, control clone; PSP, paclitaxel-surviving population.
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suntransformed cells to paclitaxel. For this purpose, we evaluated
the effects of this agent on mitotic chromosome segregation, as
well as apoptotic response of PSP sublines compared with control-
sensitive sublines (CCs). Our results clearly indicate that
paclitaxel-resistant untransformed human mammary epithelial
cells have an increased susceptibility to develop aneuploidy in
response to this agent. Our data also suggest that disruption of
microtubular network, a well-known paclitaxel-resistant mechan-
ism, could contribute to this aneuploidy-prone phenotype.
Our in vitro experiments showed that after paclitaxel treatment,
PSP sublines presented more paclitaxel-induced chromosome
missegregation than paclitaxel-sensitive sublines. Furthermore,
our results suggest that the lower level of micronucleation
observed in paclitaxel-treated CC sublines could be explained by
a rapid cell death onset that eliminates CC cells displaying dose-
dependent chromosome aberrations. Given the fact that this would
be consistent with their sensitive status, further kinetic investiga-
tion of apoptotic response to paclitaxel in these sublines will be
needed to ascertain this issue (Galmarini et al, 2006). Additionally,
PSPs also showed lower paclitaxel-induced apoptotic levels,
consistent with their previously described resistant status
(Galmarini et al, 2006). The combination of apoptosis defect with
chromosome missegregation have been extensively described as a
driving force responsible for aneuploidy in tumour cells (Hol-
lander et al, 1999; Jallepalli and Lengauer, 2001; Rajagopalan and
Lengauer, 2004; Weaver et al, 2007). Thus, our results strongly
suggest that paclitaxel-resistant untransformed mammary cells are
characterised by an aneuploidy-prone response to paclitaxel
treatment. To our knowledge, this is the first study identifying
the increased susceptibility to aneuploidisation in untransformed
human mammary epithelial cells as an advantage under paclitaxel
treatment.
Of note, four PSP sublines (PSP2, PSP4, PSP6 and PSP21) showed
a substantially increased level of constitutive chromosome mis-
segregation as shown by an increased level of micronuclei at
baseline. Strikingly, these four PSPs presented a diminished level of
chromosome missegregation after 1nM paclitaxel treatment. More-
over, we found that these ‘unstable’ PSPs underwent significantly
more apoptosis than ‘stable’ PSP sublines after short-term 1nM
paclitaxel treatment (CBMN assays, 30h). All these results suggest a
rapid elimination of cells in response to overmassive chromosome
aberrations. Our data would be in accordance with recent works
that indicate that high level of aneuploidy leads to cell lethality and/
or could avoid stable selection of phenotype with growth advantage
(Weaver et al, 2007). However, additional investigations will be
necessary to specify cell death response in paclitaxel-resistant
untransformed mammary cells.
Our data also revealed that aneuploidy-prone phenotype in
untransformed mammary cells could be, at least in part, driven by
alterations in the composition of microtubular network. Indeed,
the majority of PSPs presented constitutive altered levels of total
b-tubulin protein content, acetylated a-tubulin and/or class III
b-tubulin. The link between aberrant modifications of microtubule
dynamics and paclitaxel resistance was yet established in
paclitaxel-resistant cells through identification of alterations
in tubulin isotype expression and/or post-translational modifica-
tions. Indeed, several groups have described association of
increased expression of total b-tubulin, class III b-tubulin and/or
acetylated a-tubulin with paclitaxel resistance (Ohta et al, 1994;
Kavallaris et al, 1997; Ranganathan et al, 1998; Carles et al, 1999;
Banerjee, 2002). Furthermore, several studies have demonstrated
that microtubule defects, such as changes in the expression of
tubulins or mutations in the tubulins genes, can lead to
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Figure 3 Spindle pole aberrations in untransformed human mammary epithelial cells after paclitaxel treatment. (A) Double-immunofluorescence staining
was performed to detect g-tubulin (red) and a-tubulin (green). DNA was counterstained with Hoechst 33258 (blue). Panels show representative mitotic
figures of CC cells with two (2SP), three (3SP), four (4SP) or five (5SP) spindle poles. Scale bar, 10mm. (B) Representative time-lapse imaging of
chromosomes in an untreated H2B-GFP expressing HME1 cell during metaphase–telophase transition. As indicated, cytokinesis was completed 24min after
metaphase (24:00). (C) Representative time-lapse imaging of chromosomes in a 1nM paclitaxel-treated H2B-GFP expressing HME1 cell during metaphase–
telophase transition. White arrows on 07:00 panel indicate the tripolar spindle orientation. Of note, 41min (41:00) after metaphase, cell failed to enter
telophase and irreversibly arrested in a metaphase-like arrest showing unaligned chromosome (white arrow). Time, mm:ss normalised to metaphase equals
00:00. Scale bar, 10mm.
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s1997; Asakawa et al, 2006; Rosa et al, 2006). Thus, it is conceivable
that cells that exhibit paclitaxel resistance related to aberrant
tubulin expression would also show an increased susceptibility to
chromosome missegregation, as that observed in PSP sublines.
Notably, the diversity of tubulin alterations in PSP sublines did not
permit to identify specific tubulin patterns inducing drug
resistance, but rather an association between globally imbalanced
tubulin ratios and paclitaxel-induced chromosome missegregation
susceptibility. Additionally, it remains unclear how these different
modified tubulin ratios affect the stability of microtubules in PSPs
and their sensitivity to paclitaxel. However, our results indicate
that, in paclitaxel-resistant untransformed human mammary
epithelial cells, association of microtubular network disruption
with apoptosis defect could greatly contribute to trigger aneuploidy
in response to paclitaxel. As various processes could associate
microtubule defects and paclitaxel resistance, further studies
should ascertain mechanisms that impede microtubule-related cell
death initiation in PSP sublines (Davis and Johnson, 1999; Nuydens
et al, 2000; Mollinedo and Gajate, 2003). Of note, an other
interesting issue would consist in determining whether modified
tubulin expressions have been initially selected in HME1 cells
because of their paclitaxel-resistance properties or whether they
result from paclitaxel-induced aberrant but viable phenotypes.
Finally, even if our data show a dose-dependent increase of
spindle multipolarisation, associated with aberrant chromosomes
behaviour in both PSP and CC sublines after paclitaxel treatment,
no significant difference concerning this process was found
between the two sublines group. We cannot exclude that
differences could be detected at different post-paclitaxel treatment
times of analysis. Hence, further kinetic studies will be necessary to
specify the response to paclitaxel in regard to spindle pole
abnormalities in PSP sublines.
Recent works claimed that high rates of drug resistance in
cancer cells are caused by aneuploidy-catalysed generation of
resistance-specific aneusomies (Li et al, 2005; Duesberg et al,
2007). Hence, we speculate that plasticity of chromosomal
patrimony in PSPs could be linked to their ability to escape from
paclitaxel-induced apoptosis. Indeed, our results show that these
sublines are prone to acquire karyotype modifications. The
resulting massive gene dosage modifications could explain their
predisposition to acquire paclitaxel resistance. In contrast, cells
that retain chromosomal stability, unable to adapt to paclitaxel-
induced chromosome aberrations, would undergo efficient apop-
tosis. Other previous works prompt us to envisage that paclitaxel
doses that could trigger moderate aneuploidy could also efficiently
promote the acquisition of a resistant phenotype (Weaver et al,
2007). Thus, further investigations should aim to precise
interrelations between drug-resistance appearance and aneuploi-
disation in untransformed cells.
In summary, our results strongly indicate that paclitaxel
resistance in untransformed human mammary epithelial cells is
associated with the emergence of chromosome missegregation and
disrupted microtubular network. In addition, these non-cancerous
cells are deficient for paclitaxel-induced apoptosis and thus,
characterised by an aneuploidy-prone phenotype related to
paclitaxel treatment. The consequences of these paclitaxel effects
in non-tumour cells could be deleterious as the potentially
resulting chromosomal instability could promote tumorigenesis
hence the appearance of a secondary neoplasm linked to paclitaxel
treatment.
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